TP53 and ovarian carcinoma: Overall, these findings suggest that SLT, through ROS accumulation and p53 pathway activation, could serve as a promising basis for developing new ovarian cancer treatments by directly inhibiting cancer progression and enhancing the tumor immune response (196).